Author:
Xu Yuyan,Liao Wei,Chen Huanwei,Pan Mingxin
Abstract
Abstract
Background
Cancer is a major public health concern and the second leading cause of death worldwide. Various studies have reported the use of serum microRNAs (miRNAs) as non-invasive biomarkers for cancer detection. However, large-scale pan-cancer studies based on serum miRNAs have been relatively scarce.
Methods
An optimized machine learning workflow, combining least absolute shrinkage and selection operator (LASSO) analyses, recursive feature elimination (RFE), and fourteen kinds of machine learning algorithms, was use to screen out candidate miRNAs from 2540 serum miRNAs and constructed a potent diagnostic signature (Cancer-related Serum miRNA Signatures) for pan-cancer detection, based on a serum miRNA expression dataset of 38,223 samples.
Result
Cancer-related Serum miRNA Signatures performed well in pan-cancer detection with an area under curve (AUC) of 0.999, 94.51% sensitivity, and 99.49% specificity in the external validation cohort, and represented an acceptable diagnostic performance for identifying early-stage tumors. Furthermore, the ability of multi-classification of tumors by serum miRNAs in pancreatic, colorectal, and biliary tract cancers was lower than that in other cancers, which showed accuracies of 59%, 58.5%, and 28.9%, respectively, indicating that the difference in serum miRNA expression profiles among a small number of tumor subtypes was not as significant as that between cancer samples and non-cancer controls.
Conclusion
We have developed a serum miRNA signature using machine learning that may be a cost-effective risk tool for pan-cancer detection. Our findings will benefit not only the predictive diagnosis of cancer but also a preventive and more personalized screening plan.
Funder
Self-funded science and technology plan project of Foshan
Guangdong Medical Research Fund
Science and Technology Projects in Guangzhou of China
Guangdong Basic and Applied Basic Research Foundation of China
Provincial Science and Technology Award Cultivation Project Warehousing
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Bray F, Laversanne M, Weiderpass E, et al. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. https://doi.org/10.1002/cncr.33587.
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.
3. Kelley KD, Aronowitz P. Cancer. Med Clin North Am. 2022;106(3):411–22. https://doi.org/10.1016/j.mcna.2021.12.006.
4. WHO, Cancer Control: early detection, (2007). https://www.who.int/publications/i/item/9789241547338.
5. Cancer Survival in England, cancers diagnosed 2015 to 2019, followed up to 2020[R].